- Consumer genetic testing company 23andMe Holding ( NASDAQ: ME ) announced Thursday that the FDA granted 510(k) clearance for its pharmacogenetics report on the SLCO1B1 gene to include drug information for simvastatin, a commonly used anti-cholesterol agent.
- Changes to the SLCO1B1 gene impact the response to simvastatin which, according to the company, is ranked as the thirteenth most-commonly prescribed drug and second most commonly prescribed statin in the U.S.
- The modification to labeling info on the SLCO1B1 Drug Transport report allows the company to deliver drug information based on genetic factors driving simvastatin response.
- “This is an important win for consumers, as they will have access to critical information on how they may respond to a commonly prescribed medication, based on their genetics,” Noura Abul-Husn, 23andMe’s ( ME ) Vice President of Genomic Health, remarked .
- Read: According to Seeking Alpha contributor The Software Side of Life, 23andMe ( ME ) could be an attractive buyout target.
For further details see:
23andMe cleared in U.S. to provide cholesterol drug info in Drug Transport report